Diamyd Medical Achieves Important Patent Milestone
Diamyd Medical is excited to share that the United States Patent and Trademark Office has issued a Notice of Allowance for its critical patent covering the intralymphatic administration of retogatein (rhGAD65) combined with alum aimed at preventing and treating type 1 diabetes.
Strengthening Global Intellectual Property
This newly allowed U.S. patent application belongs to a family of patents that have already been granted in various regions including Europe, Australia, and several other countries across the globe. The issuance of this patent will significantly enhance Diamyd Medical's international patent protection for a vital part of its antigen-specific immunotherapy approach.
Milestone in Type 1 Diabetes Treatment
The patent, once granted, is expected to remain valid until 2035, adding layers of protection as the company pushes forward in its mission. Ulf Hannelius, President and CEO of Diamyd Medical, expressed the importance of this achievement, stating, "This Notice of Allowance provides us with vital intellectual property rights that support our precision medicine and antigen-specific immunotherapy ventures targeting type 1 diabetes. Securing a patent in the U.S. is a monumental step as we aim for potential commercialization of retogatein."
Current Clinical Trials and Expectations
The methodology protected by this patent is already being utilized in the ongoing Phase 3 confirmatory trial named DIAGNODE-3. This trial involves children, adolescents, and adults recently diagnosed with Stage 3 type 1 diabetes. An interim efficacy report aligned with FDA standards from this clinical trial is anticipated by the end of March 2026, providing further insights into the treatment's effectiveness.
Regulatory Market Exclusivity
Retogatein, being a biological product, can also benefit from regulatory market exclusivity in both the U.S. and Europe. This exclusivity is available independent of patent protection, subject, of course, to valid regulatory approvals.
About Diamyd Medical
Diamyd Medical specializes in developing innovative precision medicine therapies aimed at preventing and treating type 1 diabetes. The investigational therapy retogatein (rhGAD65) is designed in conjunction with alum, focusing on creating antigen-specific immune tolerance to GAD65 while preserving the natural insulin production within patients who test positive for the HLA DR3-DQ2 genetic marker.
Recognitions and Designations
This medication has already received Orphan Drug Designation from the U.S. and Fast Track Designation from the U.S. FDA for its efficacy in managing Stage 3 type 1 diabetes. The Fast Track status has also been granted for treatment under Stage 1 and Stage 2 conditions.
Global Clinical Operations
The DIAGNODE-3 trial has commenced across 57 clinics in eight different countries in Europe and the U.S., focusing on patients diagnosed with type 1 diabetes in its recent onset phase. Prior studies have highlighted significant findings related to preserving endogenous insulin production from a larger cohort of genetically predefined patients.
Future Manufacturing and Collaboration
A biomanufacturing facility is in the works in Umeå, Sweden, dedicated to producing retogatein, the active component of this promising antigen-specific immunotherapy. Diamyd Medical is also a significant stakeholder in NextCell Pharma AB and MainlyAI AB, illustrating its commitment to advancing healthcare solutions.
Contacting Diamyd Medical
If you seek further information about Diamyd Medical and its pioneering work, please reach out to:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
Frequently Asked Questions
What is the significance of the Notice of Allowance for Diamyd Medical?
The Notice of Allowance is a crucial step in securing patent protections that fortify Diamyd Medical's position in developing treatments for type 1 diabetes.
What does the patent cover?
The patent covers the intralymphatic administration of retogatein with alum as an innovative method for managing type 1 diabetes.
What is the expected timeline for the Phase 3 trial results?
An interim efficacy readout from the ongoing Phase 3 DIAGNODE-3 trial is expected to be released by March 2026.
What designations has retogatein received from regulatory bodies?
Retogatein has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA, especially targeting different stages of type 1 diabetes.
How is Diamyd Medical positioning itself in the market?
Diamyd Medical is strengthening its patent portfolio and clinical trial pipelines while also expanding its manufacturing capabilities, showcasing its commitment to innovation.
